How people puff IQOS Iluma i vs IQOS 2.4 and how flavors feel
Official title: Puff Topography and Sensory Effects Across IQOS Device Generations: A Randomized Crossover Study
Run by American University of Beirut Medical Center · NCT07712887 · Data updated 2026-11-12
This study tests how exclusive IQOS users puff the newer Iluma i versus the older 2.4, and whether preferred flavor affects puffing and sensory experience.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | American University of Beirut Medical Center Academic / other |
| Locations | 2 sites (Beirut, Beirut and 1 other locations) |
| Status | Recruiting |
| Started | July 27, 2026 |
| Main results expected | October 1, 2027 |
| Study ends | December 15, 2027 |
| Registry record updated | July 30, 2026 |
| Trial ID | NCT07712887 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18-65 who currently use IQOS at least 3 days/week and are generally healthy.
✕Probably not a fit
Individuals who do not use IQOS or who have conditions requiring nicotine cessation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized crossover study compares puff topography and sensory responses among 50 exclusive IQOS users. Participants use both IQOS Iluma i and IQOS 2.4 across two laboratory visits, with order randomized. Puffing behavior is recorded during ad-libitum use, and chemosensory ratings and subjective effects are collected after each session. The study also compares preferred versus standard flavor to see if flavor shifts influence throat hit, mouthfeel, and satisfaction. Findings will inform device-specific puffing regimens for future emissions assessments.
Why it matters
Potential benefit: If successful, results could improve understanding of real-world puffing patterns for newer IQOS devices and inform more accurate emissions testing.
How similar studies have gone: Previous work has examined puffing with traditional tobacco devices; this study extends methods to newer heated-tobacco devices and flavor conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Current IQOS user (at least 3 days per week in the past 30 days) * Age 18 to 65 years * Generally healthy * Willing to provide informed written consent * Willing to attend all laboratory visits * Willing to abstain from all nicotine and tobacco products for at least 12 hours before each visit Exclusion Criteria: * Use of any tobacco products other than IQOS in the past 30 days * Chronic cardiovascular conditions, seizures, or abnormal blood pressure * Current psychiatric disorder requiring active treatment, including major depressive disorder * Regular use of prescription medications that may influence cardiovascular function, respiratory function, or nicotine metabolism (excluding vitamins or birth control) * Use of cocaine, opioids, benzodiazepines, or methamphetamines in the past month * Marijuana use on more than 15 days per month * Current pregnancy or breastfeeding * Plans to quit nicotine or tobacco products within the next 30 days
Where it's running
-
Clinical Aerosol Technology Laboratory (CATLAB), American University of Beirut
Beirut, Beirut, Lebanon Recruiting -
Clinical Aerosol Technology Laboratory (CATLAB), American University of Beirut
Beirut, Lebanon Recruiting
Study contacts
- Principal investigator: Soha Talih — American University of Beirut Medical Center
- Study coordinator: Soha Talih, PhD
- Email: st38@aub.edu.lb
- Phone: +961-1-350000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Helping smokers practice quitting tobacco
This study is testing a new way to help smokers practice quitting tobacco by trying short breaks from smoking without pressure, comparing it to regular counseling, to see which method helps them make more quit attempts over six months.
-
One extra structured CBT session to help cancer patients quit smoking
This trial tests whether adding one CBT-based smoking-cessation session to standard brief counseling helps cancer patients quit smoking cigarettes.
-
Relapse-prevention counseling added to standard care for cancer patients who quit smoking at diagnosis
This trial tests whether adding one structured CBT-based relapse-prevention session helps cancer patients who have remained smoke-free since diagnosis stay abstinent longer.
-
Automating Tobacco Cessation in Primary Care
This project tests a workflow in primary care to identify smokers and help them access nicotine replacement therapy (NRT) during routine visits.
-
Text2Quit-Kenya: a mobile message program to help ED patients quit tobacco
Researchers will test a text message-based smoking-cessation program with Kenyan emergency department patients to see if it helps people quit and learn what works in this setting.
-
Do a single nicotine pouch affect cigarette craving and brain response to smoking cues
This study tests whether a single 6 mg oral nicotine pouch can reduce craving and alter prefrontal brain responses to smoking cues in adults who smoke cigarettes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.